» Articles » PMID: 2893706

N-oxidation of N-methylpyrrolidine Released in Vivo from Cefepime

Overview
Specialty Pharmacology
Date 1987 Nov 1
PMID 2893706
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Cefepime (BMY-28142), 7-[alpha-(2-aminothiazol-4-yl)-alpha-(Z)-methoximin oacetamido] -3-[(1-methyl-1-pyrrolidino)-methyl]-3-cephem-4-carboxylate is a potent cephalosporin that is unique in having a quaternized N-methylpyrrolidino side chain. Degradation of the beta-lactam ring can result in release of N-methylpyrrolidine (NMP), an alicyclic tertiary amine. After iv bolus administration of [methyl-14C]NMP, most radioactivity in the urine of rats and a dog was present as a polar, nonextractable metabolite, which was isolated and identified as NMP N-oxide. A minor urinary metabolite was not identified. The NMP concentration in plasma declined in a rapid monoexponential manner, and there was a concomitant increase in the N-oxide concentration. After iv administration of cefepime, which was labeled with 14C in the methyl group of the NMP side chain, 86% of the radiolabel recovered in the urine was attributable to intact antibiotic. The balance was principally present as the N-oxide. Oxidation of NMP to the N-oxide by rat and human liver microsomes was demonstrable in vitro. These results indicate that intravenously administered NMP or NMP arising from the degradation of cefepime in vivo is subject to rapid metabolic clearance.

Citing Articles

Development and validation of a volumetric absorptive microsampling- liquid chromatography mass spectrometry method for the analysis of cefepime in human whole blood: Application to pediatric pharmacokinetic study.

Moorthy G, Vedar C, Zane N, Downes K, Prodell J, DiLiberto M J Pharm Biomed Anal. 2019; 179:113002.

PMID: 31785929 PMC: 6943186. DOI: 10.1016/j.jpba.2019.113002.


Metabolism, Excretion, and Pharmacokinetics of [ C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration.

Miyazaki S, Katsube T, Shen H, Tomek C, Narukawa Y J Clin Pharmacol. 2019; 59(7):958-967.

PMID: 30730562 PMC: 6593826. DOI: 10.1002/jcph.1386.


Prospective monitoring of cefepime in intensive care unit adult patients.

Chapuis T, Giannoni E, Majcherczyk P, Chiolero R, Schaller M, Berger M Crit Care. 2010; 14(2):R51.

PMID: 20359352 PMC: 2887166. DOI: 10.1186/cc8941.


Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro.

Bugnon D, Giannoni E, Majcherczyk P, Glauser M, Moreillon P Antimicrob Agents Chemother. 2002; 46(11):3654-6.

PMID: 12384385 PMC: 128753. DOI: 10.1128/AAC.46.11.3654-3656.2002.


Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Viaene E, Chanteux H, Servais H, Mingeot-Leclercq M, Tulkens P Antimicrob Agents Chemother. 2002; 46(8):2327-32.

PMID: 12121900 PMC: 127357. DOI: 10.1128/AAC.46.8.2327-2332.2002.